Teva to Present at the Canaccord Genuity 33rd Annual Growth Conference
Teva to Present at the Canaccord Genuity 33rdAnnual Growth Conference
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYS: TEVA) will host a live audio webcast at the Canaccord Genuity 33rd Annual Growth Conference in Boston, Massachusetts. Dr. Jeremy M. Levin, President & CEO, will present on Wednesday, August 14, 2013 at 9:30 AM ET.
What: | Teva Presentation at the Canaccord Genuity 33rd Annual Growth Conference | ||
Who: | Dr. Jeremy M. Levin, President & CEO, Teva Pharmaceutical Industries Ltd. | ||
When: | Wednesday, August 14, 2013 | ||
Where: | |||
How: | Live over the Internet - log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva's website. | ||
About Teva
Teva Pharmaceutical Industries Ltd. (NYS: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.
Teva Pharmaceutical Industries Ltd.
IR Contacts:
United States
Kevin C. Mannix, 215-591-8912
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR Contacts:
Israel
Iris Beck Codner, 972 (3) 926-7246
or
United States
Denise Bradley, 215-591-8974
KEYWORDS: United States North America Massachusetts New York Middle East Israel
INDUSTRY KEYWORDS:
The article Teva to Present at the Canaccord Genuity 33rd Annual Growth Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
